Clinical observation on the effect of Chinese medicine-“TCM formula” intervention on recurrence and metastasis of triple negative breast cancer

Yi Wang,Jian-Wei Li,Yue-Nong Qin,Chen-Ping Sun,Jia-Jing Chen,Yi-Ying Ruan,Li-Xin Chen,Sheng Liu,Guang-Yu Liu
DOI: https://doi.org/10.1016/j.ctim.2020.102456
IF: 3.335
2020-08-01
Complementary Therapies in Medicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>This study used a prospective cohort study to observe the effect of triple-negative breast cancer on the 2-year disease-free survival rate with or without "TCM formula"</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>From November 1 st, 2016, the first patient was enrolled in the cohort study. A total of 356 patients were enrolled on January 30, 2019. Among them, 154 cases were followed up for 2 years. During the follow-up, there were 6 cases of shedding, so 6 cases were affected. A total of 148 cases were included in the analysis, including 73 in the exposed group and 75 in the non-exposed group. The exposed group was given "TCM formula" on the basis of standardized treatment, and the non-exposed group was treated with simple triple-negative breast cancer. The two groups visited each of the three months. The interview included safety examination (hematology and imaging). The endpoint was the difference in 2-year invasive disease-free survival between the exposed and non-exposed groups and the safety of the "TCM formula".</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>There were 6 cases of shedding during the experiment and the shedding rate was 3.9%. The 2-year rate of invasive disease-free survival in the exposed team was 88.7% and the non-exposed group was 82.5%. Logistic multivariate regression analysis predicted that "TCM formula" could reduce the disease-related recurrence and metastasis rate by 11% (OR = 0.89, 95% CI 0.37-0.956, <em>P</em>&lt;0.05). Through K-M survival analysis, TNBC patients with age ≤35 years and regional lymph node stage N1 may be the benefit group of "TCM formula"(<em>P</em>&lt;0.05). During the study, the incidence of total adverse events was 8.2% in the exposed group, mainly manifested as stomach discomfort, diarrhea, and hepatocyte damage.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>1. In the exposed group, the two-year rate of invasive disease-free survival increased by 6.2% compared with the non-exposed group(<em>P</em>&gt;0.05). 2. According to K-M survival analysis, TNBC patients with age ≤35 years and regional lymph node metastasis to N1 may be potential beneficiaries of "TCM formula". 3. "TCM Formula" is safe and tolerable to most patients</p>
integrative & complementary medicine
What problem does this paper attempt to address?
This paper aims to explore the impact of traditional Chinese medicine (TCM) prescriptions on the recurrence and metastasis of triple - negative breast cancer (TNBC). Specifically, the study uses a prospective cohort study method to observe whether the use of "TCM prescriptions" for intervention can improve the 2 - year disease - free survival rate of TNBC patients and evaluate its safety. ### Research Background Triple - negative breast cancer (TNBC) is a type of breast cancer lacking the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). This type of cancer is more common in women around 40 years old, accounting for about 15% - 20% of all breast cancer types. Compared with non - TNBC, the pathological features of TNBC are mainly invasive ductal carcinoma, and the histological grade is mostly grade III. In addition, the recurrence and metastasis rate of TNBC is relatively high. Dent et al. believe that the possibility of organ metastasis within three years after diagnosis of TNBC is four times that of non - TNBC. ### Research Objectives 1. **Primary research endpoint**: Invasive - cancer - free survival rate within 2 years after surgery. 2. **Secondary research endpoints**: Predict the risk factors and protective factors for recurrence and metastasis of TNBC patients through multivariate Logistic regression analysis, and evaluate the beneficiary population of "TCM prescriptions" through survival analysis of different subgroups. 3. **Safety research**: Evaluate drug toxicity, including acute toxicity and sub - acute toxicity, as well as liver cell damage caused by traditional Chinese medicine. ### Research Methods - **Research design**: The study is divided into two groups. The exposed group receives integrated traditional Chinese and Western medicine treatment, and the non - exposed group only receives Western medicine treatment. - **Sample size**: According to the research results of MD Anderson Cancer Center abroad, the 3 - year survival rate of TNBC patients is significantly lower than that of non - TNBC patients (74% vs 89%, P < 0.01). Considering a 20% loss - to - follow - up rate, 174 patients are required in each group. Considering the limiting factors of different hospitals, 249 patients need to be observed in each group finally. Actually, 310 patients are included. - **Inclusion criteria**: Newly diagnosed TNBC patients, Karnofsky score ≥ 60, female patients aged 18 - 75 years, expected survival time > 6 months, no serious organ or functional diseases, no drug or food allergies, and signing a written informed consent form. - **Exclusion criteria**: Patients who do not meet the inclusion criteria, patients with other tumors, patients participating in other drug trials, and patients with insufficient data. ### Research Results - **Baseline situation**: A total of 154 patients were included, including 76 in the exposed group and 78 in the non - exposed group. There were no statistical differences between the two groups in terms of age, BMI, family history, surgical method, pathological type, histological grade, and pathological stage. - **Cohort study data statistics**: The median follow - up time was 18 months (3 - 26 months). Recurrence and metastasis occurred in 8 cases in the exposed group and 13 cases in the non - exposed group. The 2 - year invasive - cancer - free survival rate in the exposed group was 88.7%, and that in the non - exposed group was 82.5%. Multivariate Logistic regression analysis showed that "TCM prescriptions" can reduce the recurrence and metastasis rate of TNBC patients by 11% (OR = 0.89, 95% CI 0.37 - 0.956, P < 0.05). - **Sub - group analysis**: TNBC patients aged ≤ 35 years may benefit more from "TCM prescriptions" (P < 0.05), and patients with regional lymph node stage N1 may also benefit (P < 0.05). - **Safety analysis**: The total incidence of adverse events in the exposed group was 8.2%, mainly manifested as stomach discomfort, diarrhea and liver cell damage. There was 1 case of serious adverse event, which may be related to traditional Chinese medicine. ### Conclusions 1. The 2 - year invasive - cancer - free survival rate in the exposed group was 6.2% higher than that in the non - exposed group, but the difference was not statistically significant (P > 0.05). 2. According to K - M survival analysis, TNBC patients aged ≤ 35 years and with regional lymph node metastasis to N1 may be potential beneficiaries of "TCM prescriptions". 3. "TCM prescriptions" are safe and tolerable for most patients.